A dermatology group can standardize its systems and still have five offices making five different decisions about modifier 25. One bills the visit, another suppresses it whenever a procedure appears, and a third sends the encounter to a coding specialist who knows which questions to ask. In dermatology medical billing, those differences determine how much work reaches the payer correctly—and how much comes back to the team.

That variation is expensive to carry into the next acquisition. Modifiers expose how consistently a group applies its reimbursement knowledge. The distinction between a separate evaluation and routine procedural work, or between two lesions and two services on the same lesion, has to survive the move from the clinical record to the claim. When it doesn’t, the billing team reconstructs the encounter through manual review, corrections, and appeals.

Modifier 25 needs evidence beyond the procedure

The modifier is easy to add, but establishing what supports it takes more judgment. Under Medicare’s NCCI guidance, the decision to perform a minor procedure is included in its payment. A separately reported E/M service requires significant, separately identifiable work beyond that decision and the usual procedural care. A new patient does not automatically qualify, and a different diagnosis is not required.

A clinician evaluates a suspicious lesion and decides to biopsy it. In another encounter, the clinician performs the biopsy and also evaluates worsening psoriasis, changing the patient’s treatment. The additional evaluation and management in the second encounter warrants review for a separate E/M service. The documentation still determines whether the service and level are supported.

Both blanket approaches fail here. Automatically adding modifier 25 can overstate what happened, while automatically removing the visit whenever a procedure appears can leave supported work unreported. The group needs a consistent way to distinguish the two before submission.

The claim needs to distinguish the lesions

A biopsy on the shoulder and destruction of an actinic keratosis on the scalp are easy to distinguish in the exam room. They become harder to distinguish when the note says only “multiple lesions treated.”

CMS’s integumentary coding guidance generally includes a biopsy of the same lesion in a lesion-removal procedure at the same encounter. A biopsy of a different lesion may be separately reportable. For edits pairing biopsy codes 11102, 11104, or 11106 with destruction codes 17000 or 17004, the qualifying distinction is separate lesions or separate encounters.

A different diagnosis code does not establish that relationship. The record needs to connect each lesion to its site and procedure. A shared lesion identifier across the note, procedure record, and pathology order gives the coding specialist evidence to follow rather than an inference to make.

For a growing group, this is a standardization decision. One practice’s “lesion A” may become another practice’s free-text site description. Agreeing on modifier use will accomplish little if the documentation feeding that decision remains inconsistent.

Adding modifier 59 can compound the mistake

A bundling denial can prompt a familiar response: add modifier 59 and resubmit. That response assumes the original claim was missing a modifier. The services may have been bundled correctly.

CMS’s modifier 59 guidance requires documentation supporting distinct services and favors a more specific modifier when appropriate. XE identifies a separate encounter; XS, a separate structure; XP, a separate practitioner; and XU, an unusual service that does not overlap the usual components of the primary service. Selection must reflect the encounter and applicable payer instructions.

The edit also limits the choice. A Medicare NCCI procedure-to-procedure edit with a modifier indicator of 0 cannot be bypassed with an NCCI-associated modifier. An indicator of 1 allows separate reporting under qualifying circumstances; it does not establish that those circumstances occurred.

Before changing the claim, identify what makes the service distinct and where the record supports it. If that evidence is missing, the next action is documentation review. A modifier cannot supply a fact the encounter never established.

Mohs billing exposes the limits of blanket rules

A simple same-lesion check can prevent inappropriate unbundling. Applied without the diagnostic context, it can also suppress a service that qualifies for separate reporting.

Mohs includes the surgeon’s pathologic examination. Its routine components should not become additional biopsy or pathology charges. Medicare’s integumentary manual also recognizes specified circumstances in which a diagnostic biopsy and pathology establish the diagnosis before proceeding to Mohs and may be separately reported.

A Medicare contractor’s Mohs billing article sets out documentation conditions involving prior biopsies and the availability of earlier results. Those instructions apply within that contractor’s coverage context. A separate lesion biopsied during the appointment presents another distinction the record must preserve. The reviewer needs the diagnostic sequence, lesion identity, prior pathology, and applicable policy together. “Biopsy plus Mohs” is enough to identify a question. It is not enough to decide the answer.

The global period follows the patient across your group

An unrelated skin condition does not stop needing care because the patient recently had surgery. But a postoperative E/M visit and an unrelated procedure require different reporting decisions.

CMS’s global surgery guidance distinguishes modifier 24 for an unrelated postoperative E/M service from modifier 79 for an unrelated procedure. Modifier 58 addresses qualifying staged or related procedures. Modifier 78 concerns an unplanned return to an operating or procedure room for a related procedure.

For Medicare, physicians in the same group and specialty are treated as a single physician for global surgery billing. Moving the follow-up to another location does not, by itself, make it separately payable.

That creates a practical test for multi-site groups: can the team reviewing today’s encounter see the original procedure and its global period, even when it happened in another office? Without that history, the coding specialist is being asked to make a relationship-based decision with only half the record. A global-period alert should bring the relevant history into review. The documented relationship between the services determines what happens next.

The next acquisition should inherit your best billing judgment

A group’s most experienced coding specialist may know which encounters need a second look, but expansion makes it harder to depend on that person being available for the right claim at the right time.

Start with a targeted review of same-day E/M and procedure claims, biopsy-plus-destruction claims, Mohs claims with additional services, and services during postoperative periods. Include paid claims: payment alone does not establish correct coding.

Then turn the findings into changes the next practice can use:

• Standardize lesion identification. Keep the site, procedure, and specimen connected from documentation through charge review.

• Route ambiguity to a qualified reviewer. Distinguish missing clinical evidence from a supported claim-data correction.
• Keep payer instructions specific. Record the policy, affected products, and effective date before applying a change across locations.
• Measure repeat work. Track modifier-related denials and recurring corrections by payer, procedure combination, and practice.

RCx helps put those standards into practice before a claim is created. Supported modifier corrections can be applied automatically, while encounters that depend on documentation or clinical context go to a qualified reviewer. Across locations, your team can apply consistent reimbursement logic and reserve specialist attention for decisions that need it.

A payer denial can prevent the next

Even a supported modifier can encounter an incorrect payer edit. In its 2026 report on private-payer advocacy, the American Academy of Dermatology Association described Aetna’s changes to modifier 59 edits for separately supported pathology services billed with Mohs.

When denials concentrate under one payer, retraining the entire group may be the wrong response. Missing documentation, a recurring claim configuration, and a payer edit that needs to be challenged each require a different action.

RemitIntel analyzes claims and remittance outcomes alongside policy signals across a network of 130,000 providers to identify recurring patterns and recommend changes to reimbursement logic. Your team reviews the supporting evidence and approves appropriate changes before Aptarro implements them. Payment experience can then inform the next claim, with specialists deciding which findings warrant a workflow change and which require further investigation.

Explore how reimbursement intelligence supports the decisions behind dermatology medical billing.